141 related articles for article (PubMed ID: 38660140)
21. Mutant p53 increases exosome-mediated transfer of miR-21-3p and miR-769-3p to promote pulmonary metastasis.
Ju Q; Zhao L; Gao J; Zhou L; Xu Y; Sun Y; Zhao X
Chin J Cancer Res; 2019 Jun; 31(3):533-546. PubMed ID: 31354222
[TBL] [Abstract][Full Text] [Related]
22. Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth.
Wang J; Chen Y; Huang C; Hao Q; Zeng SX; Omari S; Zhang Y; Zhou X; Lu H
Cancer Res; 2021 Aug; 81(15):4041-4053. PubMed ID: 34099490
[TBL] [Abstract][Full Text] [Related]
23. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
24. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP.
Wang J; Zhao Q; Qi Q; Gu HY; Rong JJ; Mu R; Zou MJ; Tao L; You QD; Guo QL
J Cell Biochem; 2011 Feb; 112(2):509-19. PubMed ID: 21268072
[TBL] [Abstract][Full Text] [Related]
25. Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation.
Roy KR; Uddin MB; Roy SC; Hill RA; Marshall J; Li YT; Chamcheu JC; Lu H; Liu YY
FASEB Bioadv; 2020 Nov; 2(11):653-667. PubMed ID: 33205006
[TBL] [Abstract][Full Text] [Related]
26. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
[TBL] [Abstract][Full Text] [Related]
27. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
[TBL] [Abstract][Full Text] [Related]
28. Targeting mutant p53 stabilization for cancer therapy.
Wang J; Liu W; Zhang L; Zhang J
Front Pharmacol; 2023; 14():1215995. PubMed ID: 37502209
[TBL] [Abstract][Full Text] [Related]
29. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
30. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
31. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.
Dong P; Tada M; Hamada J; Nakamura A; Moriuchi T; Sakuragi N
Clin Exp Metastasis; 2007; 24(6):471-83. PubMed ID: 17636407
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53
Polireddy K; Singh K; Pruski M; Jones NC; Manisundaram NV; Ponnela P; Ouellette M; Van Buren G; Younes M; Bynon JS; Dar WA; Bailey JM
Cancer Lett; 2019 Jul; 453():122-130. PubMed ID: 30946870
[TBL] [Abstract][Full Text] [Related]
33. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
34. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
35. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917
[TBL] [Abstract][Full Text] [Related]
36. CircSCAP interacts with SF3A3 to inhibit the malignance of non-small cell lung cancer by activating p53 signaling.
Chen D; Zhou H; Cai Z; Cai K; Liu J; Wang W; Miao H; Li H; Li R; Li X; Chen Y; Wang HY; Wen Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):120. PubMed ID: 35365208
[TBL] [Abstract][Full Text] [Related]
37. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
38. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.
Zhang W; Yi B; Wang C; Chen D; Bae S; Wei S; Guo RJ; Lu C; Nguyen LL; Yang WH; Lillard JW; Zhang X; Wang L; Liu R
Clin Cancer Res; 2016 May; 22(10):2545-54. PubMed ID: 26712693
[TBL] [Abstract][Full Text] [Related]
39. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
40. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis.
Sun S; Chen H; Sun L; Wang M; Wu X; Xiao ZJ
Cell Death Dis; 2020 Jul; 11(7):595. PubMed ID: 32733026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
